Public Health Impact and Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination in US Adults Aged 60 Years with Cardiopulmonary Disease
Author(s)
Elizabeth La, PhD1, David Singer, PharmD, MS1, Coline Dubois de Gennes, PharmD2, Jonathan Graham, BS3, Mei Grace, MSc3, Sara Poston, PharmD1, Frederik Verelst, PhD4;
1GSK, Philadelphia, PA, USA, 2GSK, London, United Kingdom, 3RTI Health Solutions, Research Triangle Park, NC, USA, 4GSK, Wavre, Belgium
1GSK, Philadelphia, PA, USA, 2GSK, London, United Kingdom, 3RTI Health Solutions, Research Triangle Park, NC, USA, 4GSK, Wavre, Belgium
Presentation Documents
OBJECTIVES: Risk of severe respiratory syncytialvirus (RSV) disease is increased among adults with cardiopulmonary disease.This study modeled the public health impact and cost-effectiveness ofadjuvanted RSVPreF3 vaccination in US adults ≥60 years of age (YOA) with specificprevalent cardiopulmonary diseases.
METHODS: RSV-related health and cost outcomes withand without one-time adjuvanted RSVPreF3 vaccination were estimated using astatic multi-cohort Markov model. Analyses included adults ≥60 YOA with chronicobstructive pulmonary disease (COPD; n=9,728,877), asthma (n=6,710,866), heartfailure (HF; n=5,318,193), or coronary artery disease (CAD; n=15,154,814). Themodel used a 5-year time horizon and assumed the same uptake as for influenzavaccines (60-64 YOA: 46.2%; ≥65 YOA: 69.7%). Other inputs were obtained from literature,public sources, and clinical trial results. Key incremental outcomes (e.g., RSVlower respiratory tract disease [LRTD] cases) and incrementalcost-effectiveness ratios were calculated.
RESULTS: Among adults ≥60 YOA with cardiopulmonary disease, adjuvanted RSVPreF3 vaccination was associated with fewer RSV-LRTD cases, healthcare resource use, and deaths. The largest impact was projected for CAD, where vaccinating approximately 9.7 million adults ≥60 YOA with CAD resulted in 754,446 fewer RSV-LRTD cases over 5 years, avoiding 157,906 RSV-related hospitalizations and 16,395 RSV-related deaths. For the other modeled populations, avoided RSV-LRTD cases ranged from 262,883 (HF) to 497,216 (COPD), avoided RSV-related hospitalizations ranged from 39,512 (asthma) to 157,676 (COPD), and avoided RSV-related deaths ranged from 4,024 (asthma) to 16,202 (COPD) over 5 years. Across all modeled populations, adjuvanted RSVPreF3 vaccination was dominant versus no vaccination, resulting in societal cost savings (range: $1.6 billion [asthma] to $8.1 billion [COPD]) and fewer quality-adjusted life year losses.
CONCLUSIONS: Adjuvanted RSVPreF3 vaccination among adults ≥60 YOA with cardiopulmonary disease was projected to reduce both RSV disease burden and societal costs. However, achieving these outcomes in real-world practice would require efforts to improve RSV vaccination uptake. Funding: GSK (VEO-000319).
METHODS: RSV-related health and cost outcomes withand without one-time adjuvanted RSVPreF3 vaccination were estimated using astatic multi-cohort Markov model. Analyses included adults ≥60 YOA with chronicobstructive pulmonary disease (COPD; n=9,728,877), asthma (n=6,710,866), heartfailure (HF; n=5,318,193), or coronary artery disease (CAD; n=15,154,814). Themodel used a 5-year time horizon and assumed the same uptake as for influenzavaccines (60-64 YOA: 46.2%; ≥65 YOA: 69.7%). Other inputs were obtained from literature,public sources, and clinical trial results. Key incremental outcomes (e.g., RSVlower respiratory tract disease [LRTD] cases) and incrementalcost-effectiveness ratios were calculated.
RESULTS: Among adults ≥60 YOA with cardiopulmonary disease, adjuvanted RSVPreF3 vaccination was associated with fewer RSV-LRTD cases, healthcare resource use, and deaths. The largest impact was projected for CAD, where vaccinating approximately 9.7 million adults ≥60 YOA with CAD resulted in 754,446 fewer RSV-LRTD cases over 5 years, avoiding 157,906 RSV-related hospitalizations and 16,395 RSV-related deaths. For the other modeled populations, avoided RSV-LRTD cases ranged from 262,883 (HF) to 497,216 (COPD), avoided RSV-related hospitalizations ranged from 39,512 (asthma) to 157,676 (COPD), and avoided RSV-related deaths ranged from 4,024 (asthma) to 16,202 (COPD) over 5 years. Across all modeled populations, adjuvanted RSVPreF3 vaccination was dominant versus no vaccination, resulting in societal cost savings (range: $1.6 billion [asthma] to $8.1 billion [COPD]) and fewer quality-adjusted life year losses.
CONCLUSIONS: Adjuvanted RSVPreF3 vaccination among adults ≥60 YOA with cardiopulmonary disease was projected to reduce both RSV disease burden and societal costs. However, achieving these outcomes in real-world practice would require efforts to improve RSV vaccination uptake. Funding: GSK (VEO-000319).
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE134
Topic
Economic Evaluation
Disease
STA: Vaccines